Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium-111-pentetreotide

Nai Kong V. Cheung, Brian H. Kushner, Michael Laquaglia, Kim Kramer, Smitha Gollamudi, Glenn Heller, William Gerald, Samuel Yeh, Ronald Finn, Steven M. Larson, David Wuest, Maura Byrnes, Ester Dantis, Jaume Mora, Irene Y. Cheung, Nancy Rosenfield, Sara Abramson, Richard J. O'Reilly

Research output: Contribution to journalArticle

Abstract

Background. We previously reported that human neuroblastoma cell lines and primary neuroblastoma tumors expressed a variable amount of mRNA for type 2 somatostatin (sst2) receptor gene. We also found that high level of sst2 expression were positively related to patient survival. Procedure. We studied retrospectively 49 primary neuroblastomas. To detect and measure sst2 mRNA expression we developed a quantitative RT-PCR based on competitive PCR. When possible the number of MYCN copies was also measured with competitive PCR. Results. We found that the lowest level of sst2 mRNA was detected in advanced stages of neuroblastomas (stage IV) when compared with the other stages (P< 0.005). Patients with high levels of sst2 expression (>7 × 107 molecules/γg RNA) had a cumulative survival better than those with low sst2 expression (P < 0.0005). This predictive independent value of sst2 (P = 0.005) is retained after stratification for N-myc amplification. Finally we verified that the ex vivo sst2 gene expression in tumor samples was positively related (P< 0.01) to the in vivo semiquantitative determination of sst2 protein, assessed by 111In-pentetreotide imaging. Conclusions. Our data indicate that the measurement of sst2 mRNA measurement could represent a relevant tool in the prediction of neuroblastoma outcome, independently from MYCN amplification.

Original languageEnglish (US)
Pages (from-to)224-226
Number of pages3
JournalMedical and Pediatric Oncology
Volume36
Issue number1
DOIs
StatePublished - Jan 27 2001
Externally publishedYes

    Fingerprint

Keywords

  • MYCN amplification
  • Prognosis
  • Quantitative RT-PCR
  • SPECT

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Cheung, N. K. V., Kushner, B. H., Laquaglia, M., Kramer, K., Gollamudi, S., Heller, G., Gerald, W., Yeh, S., Finn, R., Larson, S. M., Wuest, D., Byrnes, M., Dantis, E., Mora, J., Cheung, I. Y., Rosenfield, N., Abramson, S., & O'Reilly, R. J. (2001). Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium-111-pentetreotide. Medical and Pediatric Oncology, 36(1), 224-226. https://doi.org/10.1002/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#